International Journal of Clinical Pharmacology and Therapeutics · 2019 · 10 citations · 0 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyMedical OncologyCancer ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event ManagementImmune-related Adverse EventsImmunotherapy SafetyLung Cancer PharmacotherapyAtezolizumab TherapyImmune-mediated Adverse EventsImmune-mediated PneumonitisImmunotherapy-related PneumonitisMedication-related Adverse EventsNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
The anti-programmed cell death-ligand 1 (PD-L1) antibody atezolizumab is a promising agent for various cancers. Although immune-related adverse events (irAEs) induced by atezolizumab are rare, they can be severe. Clinical experience in irAE management is presently insufficient. Herein, we present a case of a patient with non-small cell lung cancer (NSCLC) who developed life-threatening irAEs including pneumonitis, thrombocytopenia, and cardiac dysfunction under immunotherapy with atezolizumab. Under expectant treatment and corticosteroid regimen, pneumonitis was totally resolved. However, thrombocytopenia and cardiac dysfunction did not improve. The patient sadly passed away 28 days after a single dose of atezolizumab. This case alarmed us once more to the importance of irAE management under cancer immunotherapy. .